Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.57 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14430777 | 0.85 | HRH3 (0.68) | APPHRH3BACE1 | |
| SCHEMBL13583449 | 0.81 | APP (0.66) | APPRAD52GFERMEN1KMT2A | |
| SCHEMBL13582986 | 0.79 | APP (0.54) | APPMEN1KMT2AHRH3BACE1 | |
| SCHEMBL2012514 | 0.76 | APP (0.59) | APPRAD52GFERMEN1KMT2A | |
| SCHEMBL2013035 | 0.76 | APP (0.83) | APPRAD52GFERMEN1KMT2A | |
| SCHEMBL11729429 | 0.76 | MAPKAPK2 (0.60) | APPRAD52GFERMEN1KMT2A | |
| SCHEMBL30426028 | 0.76 | RAD52 (0.46) | APPRAD52GFERMEN1KMT2A | |
| SCHEMBL27006750 | 0.76 | RAD52 (0.46) | APPRAD52GFERMEN1KMT2A | |
| SCHEMBL11726280 | 0.75 | MAPKAPK2 (0.75) | APPRAD52GFERMEN1KMT2A | |
| SCHEMBL2009445 | 0.75 | APP (0.50) | APPMEN1KMT2AHRH3BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680095-B2 | Heterocycle compounds and uses thereof for the prevention or treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-03-25 | — | — | US | disclosed |
| US-20120283256-A1 | NEW HETEROCYCLE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | UNIVERSITE LILLE 1 - SCIENCES ET TECHNOLOGIES (FR) | 2012-11-08 | — | — | US | disclosed |
| EP-2513062-A1 | 7-CHLORO-QUINOLIN-4-AMINE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | Institut National de la Santé et de la Recherche Médicale (FR) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011073322-A1 | 7-CHLORO-QUINOLIN-4-AMINE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283256-A1 | NEW HETEROCYCLE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | APP, BACE1, PSEN1 | APP 1/4885RAD52 4035/4885GFER 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.